| Literature DB >> 31238494 |
Benedikt Widholz1, Stefanos Tsitlakidis2, Bruno Reible3, Arash Moghaddam4,5, Fabian Westhauser6.
Abstract
Patient-derived mesenchymal stromal cells (MSCs) play a key role in bone tissue engineering. Various donor-specific factors were identified causing significant variability in the biological properties of MSCs impairing quality of data and inter-study comparability. These limitations might be overcome by pooling cells of different donors. However, the effects of pooling on osteogenic differentiation, proliferation and vitality remain unknown and have, therefore, been evaluated in this study. MSCs of 10 donors were cultivated and differentiated into osteogenic lineage individually and in a pooled setting, containing MSCs of each donor in equal parts. Proliferation was evaluated in expansion (assessment of generation time) and differentiation (quantification of dsDNA content) conditions. Vitality was visualized by a fluorescence-microscopy-based live/dead assay. Osteogenic differentiation was assessed by quantification of alkaline phosphatase (ALP) activity and extracellular calcium deposition. Compared to the individual setting, generation time of pooled MSCs was shorter and proliferation was increased during differentiation with significantly lower variances. Calcium deposition was comparable, while variances were significantly higher in the individual setting. ALP activity showed high variance in both groups, but increased comparably during the incubation period. In conclusion, MSC pooling helps to compensate donor-dependent variability and does not negatively influence MSC vitality, proliferation and osteogenic differentiation.Entities:
Keywords: bone tissue engineering; cell pooling; cell proliferation; donor-specific variability; human mesenchymal stromal cells; osteogenic differentiation
Mesh:
Substances:
Year: 2019 PMID: 31238494 PMCID: PMC6628337 DOI: 10.3390/cells8060633
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Overview of the experimental setup. Mesenchymal stromal cells (MSCs) of 10 patients were harvested and isolated. Next, the cells were expanded to passage 3 in cell culture flasks, and then seeded on 24 well plates. Ten replicates for the individual setting, consisting of 2 technical replicates each, and 10 replicates for the pooled setting. After designated incubation times, Alizarin Red S staining (ALZ), alkaline phosphatase activity measurement (ALP) and fluorescein diacetate (FDA)/propidium iodide (PI) staining (FDA/PI) were performed.
Patient demographics.
| Patient # | Age | Sex | BMI | Further Confounders |
|---|---|---|---|---|
| P1 | 69 | W | 22.7 | None |
| P2 | 40 | W | 28.9 | Analgesic abuse |
| P3 | 50 | M | 31.9 | Cortisone therapy |
| P4 | 73 | W | 35.1 | None |
| P5 | 29 | M | 41.6 | None |
| P6 | 31 | M | 37.1 | Cortisone therapy |
| P7 | 61 | M | 39.6 | Metabolic syndrome, nicotine and alcohol abuse |
| P8 | 62 | M | 31.8 | None |
| P9 | 39 | M | 22.4 | None |
| P10 | 42 | W | 34.3 | Nicotine abuse |
Patient #: chronological numbering of the patients. Age rounded to full years. M: male; F: female. BMI: body mass index [kg/m2]. Further confounders: list of confounders other than weight and sex influencing MSC behavior.
Figure 2Generation time and characterization of donor cells as MSC. Generation time of 10 single patients (P1–P10) and pooled cells (A). Representative pictures of red-colored fatty vacuoles after adipogenic differentiation for the pooled group after Oilred-O staining (B) and orange staining indicating chondrogenic differentiation for the pooled group in Safranin-O/Fast Green staining (C).
Evaluation of surface proteins for the pooled group necessary for MSC classification. Average with (±) standard deviation of the individual setting, composed of replicates of 10 patients. The pooled setting is represented by one replicate; therefore, no standard deviation is shown.
| Group | CD105 | CD73 | CD90 | Negative Control |
|---|---|---|---|---|
| Pooled | 99.43% | 96.59% | 98.42% | 1.14% |
| Individual | 99.44 ± 0.14% | 96.67 ± 1.60% | 98.47 ± 0.77% | 1.71 ± 0.24% |
Figure 3Evaluation of osteogenic differentiation. (A) Alizarin Red S stained extracellular calcium deposition of 2 representative patients (P4 and P9, respectively) and the pooled group over the cultivation period of 21 days. (B) Quantification of extracellular calcium deposition. (C) Quantification of ALP activity over the incubation period. (*) indicates significant differences. Individual: Data obtained from 10 patients (n = 2 technical replicates for each donor). Pooled: Data obtained from n = 10 replicates.
Figure 4Proliferation and cell survival under osteogenic differentiation conditions. (A) Visualization of viability and cell growth patterns during the incubation period of 21 days for 2 representative single patients (P4: slow growth during expansion; P9: fast growth during expansion) and the pooled setting. (B) Amount of dsDNA per sample during the incubation time. (*) indicates significant differences. Individual: data obtained from 10 patients (n = 2 technical replicates for each donor). Pooled: data obtained from n = 10 replicates.